GERMANTOWN, Wis.--(BUSINESS WIRE)--AAIPharma Services Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development and manufacturing services and Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, announce the appointments of Ted Dolan as Vice President, API Operations and Syed T. Husain as Vice President, API Business Unit.
“Mr. Dolan’s experience operating and managing teams in the chemical and pharmaceutical industries will further solidify our leadership in API manufacturing - this is an exciting time for our organization,” said Stephan Kutzer, Ph.D., Chief Executive Officer.
Mr. Dolan recently served as the Vice-President of Global Operations at Johnson Matthey. He has thirty years of operations and management experience in the refining, automotive, fine chemical, and pharmaceutical (API) industries. He has a B.S. degree in Chemical Engineering from the University of Notre Dame and an M.B.A. in Finance and Production Management from St. Joseph’s University.
Mr. Dolan said, “I am excited to join a dynamic team as we provide leading capabilities in API manufacturing.”
Addressing Mr. Husain’s appointment, Dr. Kutzer added, “Mr. Husain’s diverse experience in both Business Development and Operations will allow us to continue to provide our customers with best-in-class solutions in the API manufacturing industry.”
Mr. Husain recently served as the Head of Business Development and Business Team at Lonza. He has over 10 years of in-depth experience in sales, business development, marketing and operations. He has a B.S. degree in Chemical Engineering from the New Jersey Institute of Technology and an M.B.A. from Cornell University.
Mr. Husain said, “I am delighted to join the team, and I look forward to helping us provide the best services in the industry.”
About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The family of companies is in the portfolio of American Capital, Ltd. (NASDAQ: ACAS).